Early is Good (EIG), an Indianapolis, IN-based diagnostic solutions company focused on renal disease, closed a $4m seed funding round.
Social Capital, a Silicon Valley-based technology investment firm managed by Chamath Palihapitiya, made the investment.
The funds will be used to complete clinical trials for EIG’s first product, BCDx, a lab-developed test (LDT) for early bladder cancer detection.
Led by founder and CEO Thakshila Liyanage, Ph.D., EIG aims to enable the early, accurate, and widely accessible detection of renal system diseases, including bladder, kidney, and prostate cancers, by assessing specific biomarkers found in urine. The BCDx test uses advanced nanotechnology to quantify a panel of biomarkers found in a patient’s urine to diagnose bladder cancer and the stage of the disease.
The BCDx assay uses a single lab-developed test to evaluate a range of biomarkers from proteins, microRNAs, and mRNAs to long noncoding RNAs. The non-invasive technology does not require extraction or amplification and uses a hybrid dual read-out method to accurately quantify specific biomarkers.
FinSMEs
03/11/2022